Abstract
Nasal endoscopy is crucial for the early detection of nasopharyngeal carcinoma (NPC), but its accuracy relies significantly on the physician’s expertise, posing challenges for primary healthcare providers. Here, we retrospectively analysed 39,340 nasal endoscopic white-light images from three high-incidence NPC centres, utilising eight advanced deep learning models to develop an Internet-enabled smartphone application, “Nose-Keeper”, that can be used for early detection of NPC and five prevalent nasal conditions and assessment of healthy individuals. Our App demonstrated a remarkable overall accuracy of 92.27% (95% Confidence Interval (CI): 90.66%-93.61%). Notably, its sensitivity and specificity in NPC detection achieved 96.39% and 99.91%, respectively, outperforming nine experienced otolaryngologists. Explainable artificial intelligence was employed to highlight key lesion areas, improving Nose-Keeper’s decision-making accuracy and safety. Nose-Keeper can assist primary healthcare providers in diagnosing NPC and related diseases efficiently, offering a valuable resource for people in high-incidence NPC regions to manage nasal cavity health effectively.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author is supported by the NSF of Guangdong Province (No.2022A1515011044, No.2023A1515010885), and the project of promoting research capabilities for key constructed disciplines in Guangdong Province (No.2021ZDJS028).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics Committee of the Second Affiliated Hospital of Shenzhen University, the Institutional Review Board of Leizhou People's Hospital and the Ethics Committee of Foshan Sanshui District People's Hospital (reference numbers: BY-EC-SOP-006-01.0-A01, BYL20220531 and SRY-KY-2023045) and adhered to the principles of the Declaration of Helsinki. Due to the retrospective nature of the study and the use of unidentified data, the Institutional Review Boards of SZH, FSH and LZH exempted informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
A subsample of the internal test set with 110 images per diagnostic class is available upon reasonable request from the authors.
